Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | BMP1 | P13497 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14811912 | 0.95 | MC4R (0.57) | MC4RKISS1RNPBWR1CCKBR | |
| SCHEMBL22485392 | 0.93 | MC4R (0.54) | MC4RKISS1RNPBWR1PRKACBC5AR1 | |
| SCHEMBL22485368 | 0.93 | MC4R (0.50) | MC4RKISS1RNPBWR1PRKACBC5AR1 | |
| SCHEMBL22485206 | 0.91 | MC4R (0.50) | MC4RKISS1RNPBWR1CTSLCTSS | |
| SCHEMBL22339064 | 0.90 | MC4R (0.55) | MC4RKISS1RNPBWR1CCKBR | |
| SCHEMBL5501891 | 0.89 | KISS1R (0.55) | MC4RKISS1RNPBWR1 | |
| SCHEMBL14117706 | 0.89 | MC4R (0.55) | MC4RKISS1RNPBWR1CTSLCTSS | |
| SCHEMBL15691474 | 0.87 | NPBWR1 (0.52) | MC4RKISS1RNPBWR1CTSLCTSS | |
| SCHEMBL22339062 | 0.87 | NPY4R (0.55) | MC4RKISS1R | |
| SCHEMBL29511100 | 0.87 | C5AR1 (0.51) | MC4RKISS1RNPBWR1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704134-B1 | ANTIMICROBIAL TETRAPEPTIDES | DSM IP ASSETS BV (NL) | 2021-12-22 | — | — | EP | disclosed |
| US-20200308222-A1 | ANTIMICROBIAL TETRAPEPTIDES | DSM IP ASSETS B.V. (NL) | 2020-10-01 | — | — | US | disclosed |
| WO-2020161255-A1 | NOVEL METHOD FOR REDUCING HAIR GROWTH | DSM IP ASSETS B.V. (NL) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308222-A1 | ANTIMICROBIAL TETRAPEPTIDES | VIP, CLPP, SGTA | MC4R 1528/4885KISS1R 3604/4885NPBWR1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.